2024
van der Velden S, van Osch TLJ, Seghier A, Bentlage AEH, Mok JY, Geerdes DM, van Esch WJE, Pouw RB, Brouwer MC, Jongerius I, de Haas M, Porcelijn L, van der Schoot CE, Vidarsson G, Kapur R. Complement activation drives antibody-mediated transfusion-related acute lung injury via macrophage trafficking and formation of NETs. Blood, 2024, 143 (1): 79–91.
2023
Golomingi M, Kohler J, Lamers C, Pouw RB, Ricklin D, Dobó J, Gál P, Pál G, Kiss B, Dopler A, Schmidt CQ, Hardy ET, Lam W, Schroeder V. Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels. Front. Immunol., 2023, 14:1226832.
de Boer ECW, Thielen AJF, Langereis JD, Kamp A, Brouwer MC, Oskam N, Jongsma ML, Baral AJ, Spaapen RM, Zeerleder S, Vidarsson G, Rispens T, Wouters D, Pouw RB, Jongerius I. The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation. Clin. Transl. Immunology. 2023 Jan 27;12(1):e1436.
Bechtler C, Koutsogiannaki S, Umnyakova E, Hamid A, Gautam A, Sarigiannis Y, Pouw RB, Lamers C, Rabbani S, Schmidt CQ, Lambris JD, Ricklin D. Complement-regulatory biomaterial coatings: activity and selectivity profile of the factor H-binding peptide 5C6. Acta Biomater. 2023 Jan 1;155:123-138
2022
Hibender S, Li S, Postma AV, Hoogeland ME, Klaver D, Pouw RB, Niessen HW, Driessen AHg, Koolbergen DR, de Vries CJM, Baars MJh, Houweling AC, Krijnen PA, de Waard V. No prominent role for complement C1-esterase inhibitor in Marfan syndrome mice. Vasc. Biol. 2022 Oct 1;VB-22-0016
Banerjee P*, Veuskens B*, Goicoechea de Jorge E, Józsi M, Baeumner AJ, Steiner M, Pouw RB, Toonen EJM, Pauly D, Poppelaars F. Evaluating the clinical utility of measuring levels of factor H and the related proteins. Mol. Immunol. 151; 166-182, 2022
*shared first-authorship
Kumar V*, Pouw RB*, Autio MI*, Sagmeister MG*, Phua ZY, Borghini L, Wright VJ, Hoggart C, Pan B, Tan AKY, Binder A, Brouwer MC, Pinnock E, De Groot R, Hazelzet J, Emonts M, Van Der Flier M, Reiter K, Nöthen MM, Hoffmann P, EUCLIDS consortium, Schlapbach LJ, Bellos E, Anderson S, Secka F, Martinón-Torres F, Salas A, Fink C, Carrol ED, Pollard AJ, Coin LJ, Zenz W, Wouters D, Ang LT, Hibberd ML, Levin M, Kuijpers TW, Davila S. Variation in CFHR3 determines susceptibility to meningococcal disease by controlling factor H concentrations. AJHG, 109, 1–12, 2022
*shared first-authorship
van Beek AE*, Pouw RB*, Wright VJ, Sallah N, Inwald D, Hoggart C, Brouwer MC, Galassini R, Thomas J, Calvo-Bado L, Fink CG, Jongerius I, Hibberd M, Wouters D, Levin M, Kuijpers TW. Low levels of factor H family proteins during meningococcal disease indicate systemic processes rather than specific depletion by Neisseria meningitidis Front. Immunol. 13: 876776, 2022
*shared first-authorship
2021
Pouw RB, Ricklin D. Tipping the balance: intricate roles of the complement system in disease and therapy Semin. Immunopathol. 2021
van Beek AE, Pouw RB, Wright VJ, Sallah N, Inwald D, Hoggart C, Brouwer MC, Galassini R, Thomas J, Calvo-Bado L, Fink C, Jongerius I, Hibberd M, Wouters D, Levin M, Kuijpers TW. Loss of Factor H family proteins associates with meningococcal disease severity MedRxiv, 2021
Hevey R, Pouw RB, Harris CL, Ricklin D. Sweet Turning Bitter: Carbohydrate Sensing of Complement in Host Defence and Disease Brit. J. Pharmacology 178: 2802–2822, 2021
2019
Pouw RB, Brouwer MC, de Gast M, van Beek AE, van den Heuvel LP, Schmidt CQ, van der Ende A, Sánchez-Corral P, Kuijpers TW, Wouters D. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera Blood Adv. 3: 621–632, 2019
Kasanmoentalib ES, Valls Serón M, Engelen-Lee JY, Tanck MW, Pouw RB, van Mierlo G, Wouters D, Pickering MC, van der Ende A, Kuijpers TW, Brouwer MC, van de Beek D. Complement factor H contributes to mortality in humans and mice with bacterial meningitis J. Neuroinflammation 16: 1–14, 2019
2018
Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial Mol. Immunol. 102: 89–119, 2018
Sánchez-Corral P, Pouw RB, López-Trascasa M, Józsi M. Self-damage caused by dysregulation of the complement alternative pathway: Relevance of the factor H protein family Front. Immunol. 9: 1607, 2018
Pouw RB, Brouwer MC, van Beek AE, Józsi M, Wouters D, Kuijpers TW. Complement factor H-related protein 4A is the dominant circulating splice variant of CFHR4 Front. Immunol. 9: 729, 2018
Pouw RB, Gómez Delgado I, López Lera A, Rodríguez de Córdoba S, Wouters D, Kuijpers TW, Sánchez-Corral P. High complement factor H-related (FHR)-3 levels are associated with the atypical hemolytic-uremic syndrome-risk allele CFHR3*B Front. Immunol. 9: 848, 2018
2017
van Beek AE, Pouw RB, Brouwer MC, van Mierlo G, Ooijevaar-de Heer P, de Boer M, van Leeuwen K, Rispens T, Wouters D, Kuijpers TW. FHR-1 and FHR-2 form homo- and heterodimers, while FHR-5 circulates only as homodimer in human plasma Front. Immunol. 8: 1328, 2017
2016
Schäfer N, Grosche A, Reinders J, Hauck S, Pouw RB, Kuijpers TW, Wouters D, Ehrenstein B, Enzmann V, Zipfel PF, Skerka C, Pauly D. Complement regulator FHR-3 is elevated either locally or systemically in a selection of autoimmune diseases Front. Immunol. 7: 542, 2016
Pouw RB, Brouwer MC, Geissler J, van Herpen L V, Zeerleder SS, Wuillemin WA, Wouters D, Kuijpers TW. Complement factor H-related protein 3 serum levels are low compared to factor H and mainly determined by gene copy number variation in CFHR3 PLoS One 11: e0152164, 2016
2015
Pouw RB, Vredevoogd DW, Kuijpers TW, Wouters D. Of mice and men: the factor H protein family and complement regulation Mol. Immunol. 67: 12–20, 2015
Keizer MP, Pouw RB, Kamp AM, Patiwael S, Marsman G, Hart MH, Zeerleder SS, Kuijpers TW, Wouters D. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2 Eur. J. Immunol. 45: 544–550, 2015